Indications
For which patients is Gilenya ® used?
GILENYA ® (fingolimod) is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of...
For which patients is Gilenya ® used?
GILENYA ® (fingolimod) is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of...
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
KISQALI is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as...
The official patient information leaflet for EXJADE contains important information about its use and possible side effects. Patients can ask for the patient information leaflet at any time and...